Global pharma giant Bayer has inked a three-year deal with the University of Texas' MD Anderson Cancer Center to run clinical trials, matching its investigators with patient-serving oncologists in a deep-seated collaboration.
Belgium's Genae has expanded its European footprint, cutting the ribbon on a Swiss office with its eye on a bigger share of the market for medical device development.
U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.
Parexel International startled investors last quarter when its net new business dropped 30% from the previous three months.
Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.
Charles River Laboratories has convinced the CEO of Memorial Sloan-Kettering Cancer Center to join its board of directors, leading a new committee to ensure the CRO stays on the cutting edge of science.
European CRO Venn Life Sciences is back at the buyer's table, picking up Ireland's Medevol in a deal worth just over $1 million.
Massachusetts CRO Agilux Laboratories has expanded its in vivo pharmacokinetics footprint, boosting its ability to run preclinical drug-response tests for a growing list of clients.
CRO Sarah Cannon Research Institute has acquired Connecticut's Clinical Development Group, a trial consulting outfit with a wide range of offerings in oncology R&D.
The transactional model that once accounted for all CRO business is rapidly losing steam, Parexel International tells Outsourcing-Pharma, as Big Pharma sponsors recognize the benefits of deeper-seated strategic partnerships
Global R&D spending is unlikely to grow by much more than single digits over the next 5 years, but that won't do much harm to the world's biggest CROs, according to a Morningstar analyst, as the industry's heavyweights are only digging deeper into the operations of their sponsors.
CRO Aptuit has named Jonathan Goldman as its next CEO, recruiting a veteran from rival Icon and rounding out its executive suite after months of shakeups.
Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.
As CROs around the world weigh the benefits of developing their own therapies, South Korea's SillaJen has signed a deal worth up to $150 million to acquire former client Jennerex and inherit the company's Phase III-ready cancer vaccine.
Fresh off a $25 million IPO, Evoke is riding into Phase III with its gastroparesis-treating nasal spray, and now the biotech has recruited SynteractHCR to serve as its go-to CRO for the late-stage effort.
Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.
Three of India's biggest CROs are joining forces to cash in on U.S. demand for outsourced drug services, launching a combined venture called Axcellerate Pharma.
Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.
Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.